TY - JOUR
T1 - High prevalence of extended-spectrum beta-lactamases in Escherichia coli strains collected from strictly defined community-acquired urinary tract infections in adults in China
T2 - A multicenter prospective clinical microbiological and molecular study
AU - Jia, Peiyao
AU - Zhu, Ying
AU - Li, Xue
AU - Kudinha, Timothy
AU - Yang, Yang
AU - Zhang, Ge
AU - Zhang, Jingjia
AU - Xu, Yingchun
AU - Yang, Qiwen
N1 - Funding Information:
This study was supported by the National Natural Science Foundation of China (82072318) and National Key Research and Development Program of China (2018YFE0101800 and 2018YFC1200105). This study was also supported by the China Pharmacists Association, Beijing Key Clinical Specialty for Laboratory Medicine—Excellent Project (No. ZK201000).
Funding Information:
Funding. This study was supported by the National Natural Science Foundation of China (82072318) and National Key Research and Development Program of China (2018YFE0101800 and 2018YFC1200105). This study was also supported by the China Pharmacists Association, Beijing Key Clinical Specialty for Laboratory Medicine?Excellent Project (No. ZK201000).
Publisher Copyright:
© Copyright © 2021 Jia, Zhu, Li, Kudinha, Yang, Zhang, Zhang, Xu and Yang.
PY - 2021/7/7
Y1 - 2021/7/7
N2 - Objective: The objective of the study was to
investigate the antimicrobial susceptibility and extended-spectrum
beta-lactamase (ESBL) positive rates of Escherichia coli from community-acquired urinary tract infections (CA-UTIs) in Chinese hospitals.
Materials and Methods: A total of 809 E. coli
isolates from CA-UTIs in 10 hospitals (5 tertiary and 5 secondary
hospitals) from different regions in China were collected during the
period 2016–2017 according to the strict inclusion criteria.
Antimicrobial susceptibility testing was carried out by standard broth
microdilution method. Isolates were categorized as ESBL-positive,
ESBL-negative, and ESBL-uncertain groups according to the CLSI
recommended phenotypic screening method. ESBL and AmpC genes were
amplified and sequenced on ESBL-positive and ESBL-uncertain isolates.
Results: The antimicrobial agents with
susceptibility rates of greater than 95% included imipenem (99.9%),
colistin (99.6%), ertapenem (98.9%), amikacin (98.3%), cefmetazole
(97.9%), nitrofurantoin (96%), and fosfomycin (95.4%). However,
susceptibilities to cephalosporins (varying from 58.6% to 74.9%) and
levofloxacin (48.8%) were relatively low. In the phenotypic detection of
ESBLs, ESBL-positive isolates made up 38.07% of E. coli strains
isolated from CA-UTIs, while 2.97% were ESBL-uncertain. Antimicrobial
susceptibilities of imipenem, cefmetazole, colistin, ertapenem,
amikacin, and nitrofurantoin against ESBL-producing E. coli
strains were greater than 90%. The percentage of ESBL-producing strains
was higher in male (53.6%) than in female patients (35.2%) (p < 0.001). CTX-M-14 (31.8%) was the major CTX-M variant in the ESBL-producing E. coli, followed by CTX-M-55 (23.4%), CTX-M-15 (17.5%), and CTX-M-27 (13.3%). The prevalence of carbapenem-resistant E. coli among CA-UTI isolates was 0.25% (2/809).
Conclusion: Our study indicated high prevalence of ESBL in E. coli
strains from strictly defined community-acquired urinary tract
infections in adults in China. Imipenem, colistin, ertapenem, amikacin,
and nitrofurantoin were the most active antimicrobials against
ESBL-positive E. coli isolates. blaCTX–M–14 is the predominant esbl
gene in ESBL-producing and ESBL-uncertain strains. Our study indicated
that the use of cephalosporins and fluoroquinolone needs to be
restricted for empirical treatment of CA-UTIs in China.
AB - Objective: The objective of the study was to
investigate the antimicrobial susceptibility and extended-spectrum
beta-lactamase (ESBL) positive rates of Escherichia coli from community-acquired urinary tract infections (CA-UTIs) in Chinese hospitals.
Materials and Methods: A total of 809 E. coli
isolates from CA-UTIs in 10 hospitals (5 tertiary and 5 secondary
hospitals) from different regions in China were collected during the
period 2016–2017 according to the strict inclusion criteria.
Antimicrobial susceptibility testing was carried out by standard broth
microdilution method. Isolates were categorized as ESBL-positive,
ESBL-negative, and ESBL-uncertain groups according to the CLSI
recommended phenotypic screening method. ESBL and AmpC genes were
amplified and sequenced on ESBL-positive and ESBL-uncertain isolates.
Results: The antimicrobial agents with
susceptibility rates of greater than 95% included imipenem (99.9%),
colistin (99.6%), ertapenem (98.9%), amikacin (98.3%), cefmetazole
(97.9%), nitrofurantoin (96%), and fosfomycin (95.4%). However,
susceptibilities to cephalosporins (varying from 58.6% to 74.9%) and
levofloxacin (48.8%) were relatively low. In the phenotypic detection of
ESBLs, ESBL-positive isolates made up 38.07% of E. coli strains
isolated from CA-UTIs, while 2.97% were ESBL-uncertain. Antimicrobial
susceptibilities of imipenem, cefmetazole, colistin, ertapenem,
amikacin, and nitrofurantoin against ESBL-producing E. coli
strains were greater than 90%. The percentage of ESBL-producing strains
was higher in male (53.6%) than in female patients (35.2%) (p < 0.001). CTX-M-14 (31.8%) was the major CTX-M variant in the ESBL-producing E. coli, followed by CTX-M-55 (23.4%), CTX-M-15 (17.5%), and CTX-M-27 (13.3%). The prevalence of carbapenem-resistant E. coli among CA-UTI isolates was 0.25% (2/809).
Conclusion: Our study indicated high prevalence of ESBL in E. coli
strains from strictly defined community-acquired urinary tract
infections in adults in China. Imipenem, colistin, ertapenem, amikacin,
and nitrofurantoin were the most active antimicrobials against
ESBL-positive E. coli isolates. blaCTX–M–14 is the predominant esbl
gene in ESBL-producing and ESBL-uncertain strains. Our study indicated
that the use of cephalosporins and fluoroquinolone needs to be
restricted for empirical treatment of CA-UTIs in China.
KW - antibiotic resistance
KW - community-acquired urinary tract infections
KW - CTX-M
KW - empirical treatment
KW - Escherichia coli
KW - extended-spectrum beta-lactamase
UR - http://www.scopus.com/inward/record.url?scp=85111046249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111046249&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2021.663033
DO - 10.3389/fmicb.2021.663033
M3 - Article
C2 - 34305831
AN - SCOPUS:85111046249
SN - 1664-302X
VL - 12
SP - 1
EP - 12
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 663033
ER -